Among these drug candidates, Selonsertib, which was developed by Gilead Sciences and is the first clinical ASK1 inhibitor in the trial treatment of pulmonary arterial hypertension (PAH), diabetic kidney disease (DKD) and nonalcoholic steatohepatitis (NASH). Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.